Pharma Tips

Side Effect of Botulinum Toxin

By: Pharma Tips | Views: 1335 | Date: 19-Jun-2011

The following side effects of Botulinum toxin: Cervical Dystonia,Primary Axillary HyperhidrosisBlepharospasm,Strabismus,ImmunogenicityAllergic reactions like skin rash, itching or hives, swelling of the face, lips.Breathing problems,Changes in vision,Chest pain or tightnessEye pain, infection,Fast, irregular heartbeats,NumbnessSwallowing problems

SIDE EFFECTS
The following side effects of Botulinum toxin: 
    Cervical Dystonia
     Primary Axillary Hyperhidrosis
     Blepharospasm
      Strabismus
     Immunogenicity
     Allergic reactions like skin rash, itching or hives, swelling of the face, lips.
     Breathing problems
     Changes in vision
     Chest pain or tightness
     Eye pain, infection
     Fast, irregular heartbeats
      Numbness
     Swallowing problems

Side effects that usually do not require medical attention:
a)     Bruising or pain at site where injected
b)     Drooping eyelid
c)     Headache
d)      Nausea
e)     Sensitivity to light
f)      Tearing

1     Cervical Dystonia

In cervical dystonia patients evaluated for safety in double-blind and open-label studies following injection of BOTOX® , the most frequently reported adverse reactions were dysphagia (19%), upper respiratory infection (12%), neck pain (11%), and headache (11%).7
Other events reported in 2-10% of patients in any one study in decreasing order of incidence include: increased cough, flu syndrome, back pain, rhinitis, dizziness, and hypertonia, soreness at injection site, asthenia, oral dryness, speech disorder, fever, nausea, and drowsiness. Stiffness, numbness, diplopia, ptosis, and dyspnea have been reported rarely.

Dysphagia and symptomatic general weakness may be attributable to an extension of the pharmacology of BOTOX® resulting from the spread of the toxin outside the injected muscles.

The most common severe adverse event associated with the use of BOTOX® injection in patients with cervical dystonia is dysphagia with about 20% of these cases also reporting dyspnea. Most dysphagia is reported as mild or moderate in severity. However, it may rarely be associated with more severe signs and symptoms.

Additionally reports in the literature include a case of a female patient who developed brachial plexopathy two days after injection of 120 Units of BOTOX® for the treatment of cervical dystonia, and reports of dysphonia in patients who have been treated for cervical dystonia.

2 Primary Axillary Hyperhidrosis
The most frequently reported adverse events (3- 10% of patients) following injection of BOTOX® in double-blind studies included injection site pain and hemorrhage, non-axillary sweating, infection, pharyngitis, flu syndrome, headache, fever, neck or back pain, pruritus, and anxiety.
The data reflect 346 patients exposed to BOTOX® 50 Units and 110 patients exposed to BOTOX® 75 Units in each axilla. The clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not be predictive of rates observed in practice.

3 Blepharospasm

In a study of blepharospasm patients who received an average dose per eye of 33 Units (injected at 3 to 5 sites) of the currently manufactured BOTOX® , the most frequently reported treatmentrelated adverse reactions were ptosis (20.8%), superficial punctate keratitis (6.3%) and eye dryness (6.3%).

In this study, the rate for ptosis in the current BOTOX® treated group (20.8% of patients) was significantly higher than the original BOTOX® treated group (4.0% of patients) (p=0.014%). All of these events were mild or moderate except for one case of ptosis which was rated severe.

Other events reported in prior clinical studies in decreasing order of incidence include: irritation, tearing, lagophthalmos, photophobia, ectropion, keratitis, diplopia and entropion, diffuse skin rash and local swelling of the eyelid skin lasting for several days following eyelid injection.

In two cases of VII nerve disorder (one case of an aphakic eye), reduced blinking from BOTOX® injection of the orbicularis muscle led to serious corneal exposure, persistent epithelial defect, and corneal ulceration. Perforation occurred in the aphakic eye and required corneal grafting.

A report of acute angle closure glaucoma one day after receiving an injection of botulinum toxin for blepharospasm was received, with recovery four months later after laser iridotomy and trabeculectomy. Focal facial paralysis, syncope and exacerbation of myasthenia gravis have also been reported after treatment of blepharospasm.

4 Strabismus  


Extraocular muscles adjacent to the injection site can be affected, causing ptosis or vertical deviation, especially with higher doses of BOTOX®. The incidence rates of these adverse effects in 2058 adults who received a total of 3650 injections for horizontal strabismus are 15.7% and 16.9%, respectively.

Inducing paralysis in one or more extraocular muscles may produce spatial disorientation, double vision, or past-pointing. Covering the affected eye may alleviate these symptoms.
The incidence of ptosis was 0.9% after inferior rectus injection and 37.7% after superior rectus injection.

Ptosis (0.3%) and vertical deviation greater than two prism diopters (2.1%) were reported to persist for over six months in a larger series of 5587 injections of horizontal muscles in 3104 patients.

In these patients, the injection procedure itself caused nine scleral perforations. A vitreous hemorrhage occurred in one case and later cleared. No retinal detachment or visual loss occurred in any case. Sixteen retrobulbar hemorrhages occurred without visual loss.

Decompression of the orbit after five minutes was done to restore retinal circulation in one case. Five eyes had pupillary change consistent with ciliary ganglion damage (Adie's pupil).

One patient developed anterior segment ischemia after receiving BOTOX® injection into the medial rectus muscle under direct visualization for esotropia.

5 Immunogenicity
Formation of neutralizing antibodies to botulinum toxin type A may reduce the effectiveness of BOTOX® treatment by inactivating the biological activity of the toxin. The rate of formation of neutralizing antibodies in patients receiving BOTOX® has not been well studied.
In the phase 3 cervical dystonia study that enrolled only patients with a history of receiving BOTOX® for multiple treatment sessions, at study entry there were 192 patients with antibody assay results, of whom 33 (17%) had a positive assay for neutralizing activity. There were 96 patients in the randomized period of the phase 3 studies with valid assays at both study entry and end and who were neutralizing activity negative at entry. Of these 96, 2 patients (2%) converted to positive for neutralizing activity. Both of these converting patients were among the 52 who had received two BOTOX® treatments between the two assays; none were in the group randomized to placebo in the controlled comparison period of the study.

In the randomized period of the cervical dystonia study, patients in the BOTOX® group whose baseline assays were neutralizing antibody negative showed improvements on CDSS (n=64, mean CDSS change -2.1) while patients whose baseline assays were neutralizing antibody positive did not (n=14, mean CDSS change +1.1). However, in uncontrolled studies there are also individual patients who are perceived as continuing to respond to treatments despite the presence of neutralizing activity. Not all patients who become non-responsive to BOTOX® after an initial period of clinical response have demonstrable levels of neutralizing activity.

One patient among the 445 hyperidrosis patients with analyzed specimens showed the presence of neutralizing antibodies.
The data reflect the patients whose test results were considered positive or negative for neutralizing activity to BOTOX® in a mouse protection assay. The results of these tests are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of neutralizing activity in an assay may be influenced by several factors including sample handling, concomitant medications and underlying disease.

Previous Page Next Page

People Searching On This Page:
  • mechnsim of botox
  • cdss email loc:IN
  • nb64 email loc:IN
  • strabismus botox injections,preprative
  • vitreous test for any drug in pharmacognosy
  • www.cervical dystonia
  • botox axillary hyperhidrosis brachial plexopathy
  • neutralizing antibody for toxin

Related Pages


Therapeutic Uses of Botulinum Toxin

Therapeutic Uses of Botulinum Toxin

Articles | Pharmacognosy | Herbal Drug
Date:
19-Jun-2011  Views: 1607

Therapeutic UsesBotulinum Toxin Use in DystoniaBotulinum Toxin Use in Spasticity ...
Mechanism of Action of Botulinum Toxin

Mechanism of Action of Botulinum Toxin

Articles | Pharmacognosy | Herbal Drug
Date:
19-Jun-2011  Views: 2076

A, Release of acetylcholine at the neuromuscular junction is mediated by the assembly of a synaptic fusion complex that allows the membrane of the syn ...
Classification of Botulinum toxin

Classification of Botulinum toxin

Articles | Pharmacognosy | Herbal Drug
Date:
19-Jun-2011  Views: 1839

Types, Target, Discover of Botulinum toxin. ...
Prepration of Botulinum Toxin

Prepration of Botulinum Toxin

Articles | Pharmacognosy | Herbal Drug
Date:
19-Jun-2011  Views: 2574

The preparations of BoNT-A marketed in the United States , the United Kingdom and Europe (Dysport, by Speywood-Vaccine and Research Laboratory-Porton ...
Introduction and History of Botulinum Toxin

Introduction and History of Botulinum Toxin

Articles | Pharmacognosy | Herbal Drug
Date:
19-Jun-2011  Views: 1832

Botulinum toxin (abbreviated either as BTX or BoNT) is produced by Clostridium botulinum, a gram-positive anaerobic bacterium. The clinical syndrome o ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

43  + 6 =     
Comments
People Searched About:
Mechnsim Of Botox   |   Cdss Email Loc:IN   |   Nb64 Email Loc:IN   |   Strabismus Botox Injections,Preprative   |   Vitreous Test For Any Drug In Pharmacognosy   |   Www.Cervical Dystonia   |   Botox Axillary Hyperhidrosis Brachial Plexopathy   |   Neutralizing Antibody For Toxin   |  
Google : 261 times | Yahoo : 23 times | Bing : 205 times |